Biotech
🔥 A $425,000 Kidney Drug Just Cleared the FDA — and It Hits Two Targets No One Had Hit at Once
Vera Therapeutics just won FDA accelerated approval for TRUTAKNA, the first dual BAFF/APRIL inhibitor for IgA nephropathy — priced at $425,000 a year. Here's why the two-target bet matters.